Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Jan
17
Today In Oncology
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
HCC LLM Advice and Treatment Concordance
Can a Genetic Variant Affect the Efficacy of Abiraterone
Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo